Investigational drug · Phase 2
AZD3427
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Pulmonary Hypertension (World Health Organization Group 2), Heart Failure.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
4
Any phase or sponsor naming "AZD3427"
First trial start
2023
Apr 24, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AZD3427", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pulmonary Hypertension (World Health Organization Group 2)
- Heart Failure
Approved drugs for the same conditions: High blood pressure (hypertension) · Heart failure · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "AZD3427" as an intervention, largest first.
- A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2Pivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT05737940 · 260 participants · Start Apr 24, 2023 · Primary completion Jul 15, 2025
Drug: AZD3427; Placebo · For: Pulmonary Hypertension (World Health Organization Group 2); Heart Failure
Sites: Beverly Hills, California; La Jolla, California; New Haven, Connecticut · 60 sites in all
- Assessment of Safety, Tolerability, Immunogenicity, and Pharmacokinetics of AZD3427Pivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT04630067 · 105 participants · Start Nov 17, 2020 · Primary completion Sep 14, 2022
Drug: AZD3427; Placebo · For: Heart Failure
Sites: Little Rock, Arkansas; Glendale, California; Daytona Beach, Florida · 10 sites in all
AstraZenecaAstraZeneca (AZN)
NCT06611423 · 10 participants · Start Oct 15, 2024 · Primary completion Aug 21, 2025
Drug: AZD3427; Dopamine · For: Heart Failure With Reduced Ejection Fraction (HFrEF); Renal Impairment
Sites: Solna, Sweden
AstraZenecaAstraZeneca (AZN)
NCT04890548 · 0 participants · Start Nov 23, 2021 · Primary completion Aug 2, 2022
Drug: AZD3427 · For: Heart Failure
Newest research
PubMed records naming it or its code names, newest first.
- Re-PERFUSE: Phase 1b study of AZD3427, a novel relaxin receptor agonist, on renal perfusion in HFrEF patients.
Ufnal M, Quintana-Hayashi MP, Connolly K, et al. · ESC Heart Fail 2025
- A novel long-acting relaxin-2 fusion, AZD3427, improves cardiac performance in non-human primates with cardiac dysfunction.
Papworth M, Kulkarni S, Antonsson M, et al. · Cardiovasc Res 2025
- Relaxin mimetic in pulmonary hypertension associated with left heart disease: Design and rationale of Re-PHIRE.
Ufnal M, Connolly K, Millegard M, et al. · ESC Heart Fail 2025
- Novel Relaxin Receptor RXFP1 Agonist AZD3427 in the Treatment of Heart Failure: A Phase 1a/b, First-in-Human, Randomized, Single-Blind, Placebo-Controlled Study.
Connolly K, George R, Omar S, et al. · J Am Heart Assoc 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.